Drug Trial News

RSS

Shingles vaccine may not increase risk of varicella in people with auto-immune diseases

New research from the University of Alabama at Birmingham casts doubt on the long-standing belief that the vaccine for shingles should not be given to patients taking biologics for auto-immune diseases such as rheumatoid arthritis.

4 Jul 2012

TMC receives NIH grant to evaluate pepducin in heart disease patients

Tufts Medical Center researchers are developing a first-of-its-kind drug to prevent deadly blood clots in heart disease patients, without the risk of serious bleeding associated with current medications. The National Heart, Lung, and Blood Institute of the National Institutes of Health has just awarded the team led by Athan Kuliopulos, MD, PhD, a $10 million grant to start testing a drug based on this novel technology.

4 Jul 2012

Botulinum toxin may help prevent arm tremor in people with MS

Botulinum toxin may help prevent shaking or tremor in the arms and hands of people with multiple sclerosis (MS), according to new research published in the July 3, 2012, print issue of Neurology, the medical journal of the American Academy of Neurology.

3 Jul 2012

Savient's KRYSTEXXA improves HRQOL and physical function in patients with RCG

Savient Pharmaceuticals, Inc. announced a new publication showing that adult patients with refractory chronic gout (RCG) treated bi-weekly with KRYSTEXXA- (pegloticase) experienced statistically significant and clinically meaningful improvements in health-related quality of life (HRQOL), pain and physical function.

3 Jul 2012

ImmunoCellular to expand ICT-107 Phase IIb trial on GBM

ImmunoCellular Therapeutics, Ltd., a clinical stage biotechnology company that is focused on developing new immune-based products to treat cancer, announced today that it will expand its current Phase IIb trial of ICT-107 from 102 to up to 123 patients with glioblastoma multiforme (GBM) and who are HLA-A1/A2 positive.

2 Jul 2012

Onyx commences ENDEAVOR Kyprolis Phase 3 trial for relapsed multiple myeloma

Onyx Pharmaceuticals, Inc. announced today that the company has begun enrollment in the ENDEAVOR trial, a Phase 3 trial evaluating Kyprolis in combination with dexamethasone, versus bortezomib with dexamethasone in patients with relapsed multiple myeloma.

2 Jul 2012

Cerulean commences dosing in CRLX101-Avastin combination study for metastatic renal cell carcinoma

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 1b/2a study of its lead product candidate, CRLX101, in combination with Avastin, in metastatic renal cell carcinoma (mRCC) patients. The company also announced the completion of enrollment of its randomized Phase 2 study in advanced non-small cell lung cancer.

2 Jul 2012

Enrollment complete in Cerulean CRLX101 Phase 2 study for non-small cell lung cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.

2 Jul 2012

Rexahn submits RX-5902 IND to FDA for treatment of advanced or metastatic solid tumors

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted an investigational new drug application (IND) to the Food and Drug Administration for a first-in-human study of RX-5902 to treat advanced or metastatic solid tumors.

2 Jul 2012

Sosei completes SO-1105 Phase I trial for oropharyngeal candidiasis in Japan

Sosei Group Corporation, the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has successfully completed a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal candidiasis.

2 Jul 2012

Janssen seeks accelerated FDA approval for bedaquiline to treat MDR-TB

Janssen Research & Development, LLC today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the use of the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults.

2 Jul 2012

Clinical results for Teva's biologic oncology candidates presented at MASCC/ISOO 2012

Teva Pharmaceutical Industries Ltd. announced today the presentation of clinical results for its biologic oncology candidates, lipegfilgrastim and balugrastim, at the Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) 2012 International Symposium on Supportive Care in Cancer being held in New York June 28-30.

2 Jul 2012

A.P. Pharma announces additional data from APF530 Phase 3 study on CINV

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced additional data from the Company's Phase 3 study of APF530 for the prevention of chemotherapy-induced nausea and vomiting (CINV).

29 Jun 2012

Lexicon announces results from two initial trials of LX4211 for type 2 diabetes

Lexicon Pharmaceuticals, Inc. announced today the publication of results from two initial trials of LX4211 in patients with type 2 diabetes in the online edition of the journal Clinical Pharmacology & Therapeutics.

29 Jun 2012

Drug trial participants should be better informed about benefits and side-effects of placebos

Research carried out at the University of Southampton has concluded that participants in drug trials should be better informed about the potential significant benefits and possible side-effects of placebos.

29 Jun 2012

Once-daily pill for HIV is a safe and effective alternative to traditional antiretroviral regimens

A new once-daily pill combining three antiretrovirals and a booster molecule is a safe and effective alternative to two widely used drug regimens for newly diagnosed HIV-positive adults who have had no previous treatment. The findings of two large international randomised trials published in this week’s Lancet also indicate that the new “Quad” pill is faster acting, doesn’t have the neuropsychiatric side effects associated with other combinations, and could improve compliance with treatment.

29 Jun 2012

New drug for Type 2 diabetes results in less hypoglycaemia, less weight gain and perhaps less cardiovascular risk for patients

A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don’t respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.

29 Jun 2012

Medivir, Bristol-Myers Squibb to initiate TMC435 and daclatasvir phase II combination study in HCV

Medivir AB, the research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that a phase II combination study with the investigational compound TMC435 and Bristol-Myers Squibb's investigational compound daclatasvir will start in July.

29 Jun 2012

Results from Access’ MuGard Phase 4 trial on oral mucositis

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company developing treatments in areas of oncology and oncology supportive care, announced that Dr. Ron R. Allison of Carolina Radiation Medicine, Greenville, NC, presented results from its ongoing MuGard Phase 4 clinical trial in oral mucositis (OM) at the Multinational Association of Supportive Care in Cancer (MASCC) Conference in New York City.

29 Jun 2012

LUMC oncologist presents survival data for brentuximab vedotin at 17th EHA Congress

A new cancer drug with remarkably few side effects is dramatically improving survival in Hodgkin lymphoma patients who fail other treatments and are nearly out of options.

28 Jun 2012

Drug Trial News

Shingles vaccine may not increase risk of varicella in people with auto-immune diseases

TMC receives NIH grant to evaluate pepducin in heart disease patients

Botulinum toxin may help prevent arm tremor in people with MS

Savient's KRYSTEXXA improves HRQOL and physical function in patients with RCG

ImmunoCellular to expand ICT-107 Phase IIb trial on GBM

Onyx commences ENDEAVOR Kyprolis Phase 3 trial for relapsed multiple myeloma

Cerulean commences dosing in CRLX101-Avastin combination study for metastatic renal cell carcinoma

Enrollment complete in Cerulean CRLX101 Phase 2 study for non-small cell lung cancer

Rexahn submits RX-5902 IND to FDA for treatment of advanced or metastatic solid tumors

Sosei completes SO-1105 Phase I trial for oropharyngeal candidiasis in Japan

Janssen seeks accelerated FDA approval for bedaquiline to treat MDR-TB

Clinical results for Teva's biologic oncology candidates presented at MASCC/ISOO 2012

A.P. Pharma announces additional data from APF530 Phase 3 study on CINV

Lexicon announces results from two initial trials of LX4211 for type 2 diabetes

Drug trial participants should be better informed about benefits and side-effects of placebos

Once-daily pill for HIV is a safe and effective alternative to traditional antiretroviral regimens

New drug for Type 2 diabetes results in less hypoglycaemia, less weight gain and perhaps less cardiovascular risk for patients

Medivir, Bristol-Myers Squibb to initiate TMC435 and daclatasvir phase II combination study in HCV

Results from Access’ MuGard Phase 4 trial on oral mucositis

LUMC oncologist presents survival data for brentuximab vedotin at 17th EHA Congress

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News